This is a routine corporate presentation update with no new material information. Monitor upcoming catalysts: TILVANCE-301 interim ORR analysis, IOV-LUN-202 registrational data, and IOV-SAR-201 trial initiation in 2H 2026. The stock has shown strong positive drift on prior neutral filings, but this update alone does not provide a trading signal.
Price Chart
Executive Summary
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine administrative event. The presentation reiterates previously disclosed financial guidance (FY26 revenue $350M-$370M, Q2 2026 revenue $86M-$88M) and pipeline progress, including the TILVANCE-301 Phase 3 frontline melanoma trial and IOV-LUN-202 NSCLC registrational trial. No new material financial data or business developments were disclosed beyond what was already public.
Key Facts
- Filed 8-K to update corporate presentation used at healthcare conferences and with analysts.
- FY26 total revenue guidance reiterated at $350M-$370M.
- Q2 2026 revenue guidance reiterated at $86M-$88M.
- Cash position as of 3/31/26: ~$319M.
- Over 90 authorized treatment centers for Amtagvi as of 05/07/26.
- TILVANCE-301 Phase 3 frontline melanoma trial enrollment on track; N=670, 75+ sites globally.
- IOV-LUN-202 registrational trial in NSCLC has Fast Track Designation; potential launch in 2H27.
- IOV-SAR-201 Phase 2 registrational trial in soft tissue sarcomas to commence in 2Q 2026.
- IOV-5001 (IL-12 tethered TIL) IND-cleared; Phase 1/2 basket trial to start 2H2026.
- Cash position ~$319M as of 3/31/26, with runway into 2028.
Financial Impact
No new financial data disclosed. FY26 revenue guidance reiterated at $350M-$370M; Q2 2026 guidance at $86M-$88M. Cash position ~$319M as of 3/31/26.
Risk Factors
- Clinical trial risks: TILVANCE-301, IOV-LUN-202, and IOV-SAR-201 may fail to meet endpoints.
- Commercial execution risk: Amtagvi revenue growth may not meet guidance of $350M-$370M for FY26.
- Regulatory risk: FDA feedback on NSCLC and sarcoma registrational trials could delay timelines.
- Cash burn: ~$319M cash with runway into 2028, but profitability not yet achieved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080409 |
| Document: tm2618989d1_8k.htm | 0001104659-26-080409 |
| Document: 0001104659-26-080409-index-headers.html | 0001104659-26-080409 |
| Document: 0001104659-26-080409-index.html | 0001104659-26-080409 |
| Document: 0001104659-26-080409.txt | 0001104659-26-080409 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.24 (+76.67%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.24 (+124.61%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.24 (+129.31%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.24 (−205.58%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.24 (+230.39%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.24 (+250.74%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.24 (+259.60%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.24 (+247.32%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.24 (+330.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access